Unknown

Dataset Information

0

Characterization of novel neutralizing mouse monoclonal antibody JM1-24-3 developed against MUC18 in metastatic melanoma.


ABSTRACT: Background: MUC18 is a glycoprotein highly expressed on the surface of melanoma and other cancers which promotes tumor progression and metastasis. However, its mechanism of action and suitability as a therapeutic target are unknown.

Methods: A monoclonal antibody (mAb) (JM1-24-3) was generated from metastatic melanoma tumor live cell immunization, and high-throughput screening identified MUC18 as the target.

Results: Analysis of molecular interactions between MUC18 and JM1-24-3 revealed that the downstream signaling events depended on binding of the mAb to a conformational epitope on the extracellular domain of MUC18. JM1-24-3 inhibited melanoma cell proliferation, migration and invasion in vitro and reduced tumor growth and metastasis in vivo.

Conclusion: These results confirm that MUC18 is mechanistically important in melanoma growth and metastasis, suggest that the MUC18 epitope identified is a promising therapeutic target, and that the JM1-24-3 mAb may serve as the basis for a potential therapeutic agent.

SUBMITTER: Feng R 

PROVIDER: S-EPMC7718695 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Characterization of novel neutralizing mouse monoclonal antibody JM1-24-3 developed against MUC18 in metastatic melanoma.

Feng Runhua R   Wang Yuling Y   Ramachandran Vijaya V   Ma Qinhong Q   May Matthew M MM   Li Ming M   Zhou Joe X JX   Xu Xiang X   Xu Kejing K   Fang Shenying S   Xia Weiya W   Sui Dawen D   Liu Huey H   Gao Xiaolian X   Prieto Victor V   Blacklow Stephen C SC   Lu Mason M   Lee Jeffrey E JE  

Journal of experimental & clinical cancer research : CR 20201205 1


<h4>Background</h4>MUC18 is a glycoprotein highly expressed on the surface of melanoma and other cancers which promotes tumor progression and metastasis. However, its mechanism of action and suitability as a therapeutic target are unknown.<h4>Methods</h4>A monoclonal antibody (mAb) (JM1-24-3) was generated from metastatic melanoma tumor live cell immunization, and high-throughput screening identified MUC18 as the target.<h4>Results</h4>Analysis of molecular interactions between MUC18 and JM1-24-  ...[more]

Similar Datasets

| S-EPMC4568252 | biostudies-literature
| S-EPMC10646479 | biostudies-literature
| S-EPMC3230632 | biostudies-literature
| S-EPMC10617428 | biostudies-literature
| S-EPMC1479265 | biostudies-literature
| S-EPMC7577740 | biostudies-literature
| S-EPMC4414269 | biostudies-literature
| S-EPMC8637776 | biostudies-literature
| S-EPMC7482898 | biostudies-literature
| S-EPMC6615639 | biostudies-literature